In a report released today, Hartaj Singh from Oppenheimer maintained a Hold rating on Oncternal Therapeutics (ONCT – Research Report). The company’s shares closed yesterday at $9.70.
According to TipRanks, Singh is a 5-star analyst with an average return of 15.3% and a 46.63% success rate. Singh covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Regeneron, and Biomea Fusion.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oncternal Therapeutics with a $30.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
ONCT market cap is currently $29.13M and has a P/E ratio of -0.68.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Oncternal Therapeutics (ONCT) Company Description:
Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. Its focus is on drug development on promising yet untapped biological pathways implicated in cancer progression. The company was founded in 1997 and is headquartered in San Diego, CA.
Read More on ONCT:
- Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Oncternal Therapeutics reports inducement award under Nasdaq listing rule
- Oncternal Therapeutics target adjusted to $30 from $2 at H.C. Wainwright
- Oncternal enrolls patients into third dosing cohort of Phase 1/2 trial
